Abstract | BACKGROUND: METHODS: We will search Cochrane Library, PubMed, Wanfang Data, China National Knowledge Infrastructure, VIP Chinese Science and Technology Journals Database, and Chinese Biomedical Database from inception until October 31th, 2017. Inclusion the randomized controlled trials and clinical control trials of combine therapy which evaluate clinical efficacy and side effect in people with DPN. Data extraction and risk of bias assessments will be independently conducted by 2 reviewers. The primary outcome measures will be total effective rate, motor nerve conduction velocity (MNCV), sensory nerve conduction velocity (SNCV), Toronto clinical scoring system (TCSS), and total symptom score (TSS). All statistical analyses will be performed using RevMan V.5.3 software. RESULTS: This review will evaluate the total effective rate, nerve conduction velocity, TCSS, TSS, and safety of ALA combined with epalrestat for patients with DPN, compare with epalrestat alone. CONCLUSION: Our study will provide evidence to assess whether epalrestat combined with ALA is an optional treatment for patients with DPN.
|
Authors | Xiaotong Wang, Haixiong Lin, Shuai Xu, Yuanlin Jin, Ren Zhang |
Journal | Medicine
(Medicine (Baltimore))
Vol. 97
Issue 6
Pg. e9828
(Feb 2018)
ISSN: 1536-5964 [Electronic] United States |
PMID | 29419686
(Publication Type: Journal Article)
|
Chemical References |
- Antioxidants
- Enzyme Inhibitors
- Thiazolidines
- epalrestat
- Thioctic Acid
- Rhodanine
|
Topics |
- Antioxidants
(administration & dosage, adverse effects)
- Diabetic Neuropathies
(drug therapy)
- Drug Therapy, Combination
- Enzyme Inhibitors
(administration & dosage, adverse effects)
- Humans
- Meta-Analysis as Topic
- Randomized Controlled Trials as Topic
- Research Design
- Rhodanine
(administration & dosage, adverse effects, analogs & derivatives)
- Thiazolidines
(administration & dosage, adverse effects)
- Thioctic Acid
(administration & dosage, adverse effects)
- Treatment Outcome
|